Tesamorelin vs CJC-1295/Ipamorelin 2026: FDA vs Dual

The Core Difference

Tesamorelin and CJC-1295 both bind the GHRH receptor on pituitary somatotroph cells to stimulate growth hormone release. They are both synthetic analogs of native GHRH. The differences are in their engineering, their regulatory history, and what CJC-1295 brings to the table when paired with Ipamorelin.

Tesamorelin was engineered with a trans-3-hexenoic acid modification that protects it from DPP-IV degradation, extending its half-life from the ~7 minutes of native GHRH to approximately 26 minutes. It was developed by Theratechnologies in Montreal and received FDA approval in 2010 based on two large Phase 3 trials showing 15% visceral fat reduction.

The CJC-1295 in the combo takes a different approach to durability. It is the no-DAC version, also called Modified GRF 1-29, with four enzyme-resistant amino acid substitutions that slow DPP-IV degradation and give it a half-life of about 30 minutes. Like Tesamorelin, it is short-acting and pulsatile. When paired with Ipamorelin (a selective ghrelin receptor agonist developed by Novo Nordisk), the combination stimulates GH through two independent receptor systems. This dual-pathway approach produces amplified GH output beyond what either pathway achieves alone. A separate long-acting variant, CJC-1295 with DAC, binds albumin for a multi-day half-life, but that is a different molecule and not what this combo uses.

Side-by-Side Comparison

Tesamorelin: The FDA-Approved Option

Tesamorelin has the strongest clinical evidence of any growth hormone peptide. Two Phase 3, multicenter, randomized, double-blind, placebo-controlled trials (LIPO-010 and LIPO-011) enrolled 816 HIV-infected patients with lipodystrophy. CT-scan-measured visceral fat decreased by 15% over 26 weeks. Triglycerides improved. Lean mass was preserved. Body image scores improved.

Additional research published in The Lancet HIV (2019) showed Tesamorelin reduces hepatic (liver) fat in NAFLD, with 35% of treated patients normalizing liver fat vs 4% on placebo. Preliminary cognitive studies in older adults suggest improvements in executive function and verbal memory.

Tesamorelin's limitation is that it works through a single receptor pathway (GHRH only). It does not include the ghrelin receptor amplification that Ipamorelin provides. This is why PeRx offers the Tesamorelin/Ipamorelin combination: the FDA-approved molecule plus the dual-pathway enhancement.

CJC-1295/Ipamorelin: The Dual-Pathway Stack

CJC-1295/Ipamorelin is the most prescribed growth hormone peptide stack in the United States. Its popularity comes from the dual-pathway mechanism: CJC-1295 provides the GHRH signal, and Ipamorelin amplifies each pulse through the ghrelin receptor. Two independent receptor systems producing synergistic output.

The no-DAC CJC-1295 in the combo has a half-life of about 30 minutes, similar to Tesamorelin's roughly 26 minutes, so both are short-acting and preserve natural pulsatility. The combo's edge is not duration. It comes from adding Ipamorelin's ghrelin-receptor pulse amplification on top of the GHRH signal, which produces stronger total GH output per 24-hour period. The trade-off is less clinical trial data and no FDA approval.

Ipamorelin's selectivity is important: unlike earlier GH secretagogues (GHRP-6, GHRP-2), it stimulates GH without significantly affecting cortisol, prolactin, or ACTH. This clean side-effect profile is why it became the preferred pairing agent.

Which One Should You Choose?

Frequently Asked Questions